about
Immunotherapy for metastatic renal cell carcinomaWnt Signaling in Renal Cell CarcinomaCytoreductive surgery in the era of targeted molecular therapyThe potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapyMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibEfficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alphaTargeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.Renal cell carcinoma: molecular biology and targeted therapyClinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor typesTemsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral centerSerum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinomaIndirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis.Sunitinib for advanced renal cell cancer.ARHGAP24 inhibits cell cycle progression, induces apoptosis and suppresses invasion in renal cell carcinoma.Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.State-of-the-art treatment of metastatic renal cell carcinoma.Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.Antitumor effect and biological pathways of a recombinant adeno-associated virus as a human renal cell carcinoma suppressor.Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.Updates on novel therapies for metastatic renal cell carcinoma.Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib.Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.
P2860
Q24186688-051E6FEF-85A6-43FD-9546-99A873C4E5BCQ26744312-06FC603B-2225-4F90-8032-C408AA7F3F13Q26774134-C9C069F9-F3F7-4406-8F06-3A219EF40968Q26783291-A746B387-AD53-4B3B-9489-AD8E33963904Q26852437-5EEE9B24-3065-47BE-8551-832E1538BE85Q28765488-13AD6300-4832-48C4-8E46-CCC4C8AC1C17Q30486440-528568E6-87D0-4413-9BD6-8D51B1EC06F5Q33387073-3B2C925B-7AF9-4536-AA9A-51A5C8358BC5Q33847825-549B77AF-A860-42F1-8DA5-49DFDDE20CEFQ34032864-76964AA9-EA09-4140-A12C-14E39DD1A4A6Q34513914-157E414A-4AB1-47F0-B93A-086D499DA54BQ34669751-B7215253-40FC-45DC-8DEA-B623438639C9Q34775380-EDCF16D9-8576-4EE4-AC27-256AC017595EQ34995745-AEC18C7F-DC45-4B9E-B996-325BB67592B9Q35205445-42CF149F-BF2F-40FC-B6B9-D8A2292AA45FQ35580479-2DE362BC-F2F0-4B94-936C-2CBA691301C3Q35584879-8F8B3CAD-F1C7-4542-A2CB-AC332D7DA32FQ37253841-02FDD40B-452F-4BA2-9A77-D1E28A010F3CQ37307562-65BA3FB2-B249-441B-9F92-E60A2AA54918Q37588375-C20BF026-4604-481B-8B64-FE6B171F9DD8Q37671681-07BFED95-F410-47F7-A9C4-A1B37F85B1B5Q37687020-06E2F2B3-EDA6-4A93-8D1A-F3828EF34B55Q38860651-319922F1-6246-4D47-ACE9-EC703657AA70Q39975802-F3640E16-CD88-44EB-8111-1E93223A31A5Q40685017-1CA554B9-88B9-4FDE-A98F-2EA376C27256Q41145898-9BF60D1F-9280-4736-8466-FC0BA476438FQ41898172-94A17E58-635D-48FF-9789-A4440B165BC3Q42201994-0B06A296-53CD-4FB1-A0F8-7D8A942B5B1FQ42362967-E93E9F33-269B-4BBC-82A4-8F354109C63CQ42728990-786F42AC-EFC8-424B-AA44-FB8699308BB2Q45932398-E1A8F15B-0677-4E10-B25B-9C08FD3F07F8Q47358265-C833B0A0-DC04-4ED0-9A72-2218CD1E4233Q52884927-2467D36C-2710-418A-AE86-459057B1487B
P2860
description
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2008/04/23)
@fr
articolo scientifico (pubblicato il 2008/04/23)
@it
artigo científico (publicado na 2008/04/23)
@pt
artikull shkencor
@sq
artículu científicu espublizáu en 2008
@ast
scientific article (published 2008-04-23)
@en
vedecký článok (publikovaný 2008/04/23)
@sk
vetenskaplig artikel (publicerad på 2008/04/23)
@sv
name
Targeted therapy for advanced renal cell carcinoma
@ast
Targeted therapy for advanced renal cell carcinoma
@en
Targeted therapy for advanced renal cell carcinoma
@en-gb
Targeted therapy for advanced renal cell carcinoma
@nl
type
label
Targeted therapy for advanced renal cell carcinoma
@ast
Targeted therapy for advanced renal cell carcinoma
@en
Targeted therapy for advanced renal cell carcinoma
@en-gb
Targeted therapy for advanced renal cell carcinoma
@nl
prefLabel
Targeted therapy for advanced renal cell carcinoma
@ast
Targeted therapy for advanced renal cell carcinoma
@en
Targeted therapy for advanced renal cell carcinoma
@en-gb
Targeted therapy for advanced renal cell carcinoma
@nl
P2093
P2860
P3181
P1476
Targeted therapy for advanced renal cell carcinoma
@en
P2093
Chris Coppin
Christian Kollmannsberger
Timothy J Wilt
P2860
P3181
P356
10.1002/14651858.CD006017.PUB2
P577
2008-04-23T00:00:00Z